Screening for Cervical Cancer
Authors: Guglielmo Ronco
Journal: Annals of Internal Medicine (2012)

Letters17 April 2012Screening for Cervical CancerGuglielmo Ronco, MD, Chris J.L. Meijer, MD, Jack Cuzick, PhD, Paolo Giorgi-Rossi, PhD, Julian Peto, TSc, Nereo Segnan, MD, and Joakim Dillner, MDGuglielmo Ronco, MDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, Chris J.L. Meijer, MDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, Jack Cuzick, PhDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, Paolo Giorgi-Rossi, PhDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, Julian Peto, TScFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, Nereo Segnan, MDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this author, and Joakim Dillner, MDFrom Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-156-8-201204170-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Whitlock and colleagues' article (1) evaluated the use of human papillomavirus (HPV) testing and cytology in cervical cancer screening and concluded that more evidence is needed to determine the optimal approach. Their review evaluated the different possible screening strategies (HPV testing alone, HPV testing alone with cytology triage, HPV testing plus cytology screening [cotesting], and cotesting with cytology triage) separately versus cytology alone and considered only results on prevention of invasive cancer.Evidence has conclusively shown that HPV testing can detect approximately 50% more cases of high-grade cervical intraepithelial neoplasia (CIN), an established precursor to cancer, than ...References1. Whitlock EP, Vesco KK, Eder M, Lin JS, Senger CA, Burda BU. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:687-97, W214-5. [PMID: 22006930] LinkGoogle Scholar2. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 Suppl 10 K29-41. [PMID: 18847555] CrossrefMedlineGoogle Scholar3. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Elfgren K, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357:1589-97. [PMID: 17942872] CrossrefMedlineGoogle Scholar4. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007;370:1764-72. [PMID: 17919718] CrossrefMedlineGoogle Scholar5. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10:672-82. [PMID: 19540162] CrossrefMedlineGoogle Scholar6. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al; New Technologies for Cervical Cancer screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-57. [PMID: 20089449] CrossrefMedlineGoogle Scholar7. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance on Cervical Cancer Screening. 2nd ed. Luxembourg: Office Official Publications European Communities; 2008. Google Scholar Author, Article, and Disclosure InformationAuthors: Guglielmo Ronco, MD; Chris J.L. Meijer, MD; Jack Cuzick, PhD; Paolo Giorgi-Rossi, PhD; Julian Peto, TSc; Nereo Segnan, MD; Joakim Dillner, MDAffiliations: From Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy; VU Medical Center, 1007 MB Amsterdam, the Netherlands; Queen Mary University of London, London EC1M 6BQ, United Kingdom; Agenzia di Sanità Pubblica della Regione Lazio, 53-00198 Rome, Italy; London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom; Centro di Riferimento per l'Epidemiologia e la Prevenzione Oncologica Piemonte, 10123 Torino, Italy;and Karolinska Institute, SE-171 77 Stockholm, Sweden.Disclosures: Dr. Meijer is a member of the scientific advisory board of QIAGEN and occasional consultant for GlaxoSmithKline, Merck & Co., and Roche. Dr. Cuzick's institution receives support from Abbott, Becton Dickinson, GenProbe, QUIAGEN, and Roche to evaluate HPV tests, and he is an occasional consultant for these companies. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoLiquid-Based Cytology and Human Papillomavirus Testing to Screen for Cervical Cancer: A Systematic Review for the U.S. Preventive Services Task Force Evelyn P. Whitlock , Kimberly K. Vesco , Michelle Eder , Jennifer S. Lin , Caitlyn A. Senger , and Brittany U. Burda Correction: Liquid-Based Cytology and Human Papillomavirus Screening for Cervical CancerScreening for Cervical Cancer Evelyn P. Whitlock , Kimberly K. Vesco , Jennifer S. Lin , Michelle Eder , and Brittany U. Burda Metrics Cited byAssociation of toll-like receptor gene polymorphisms and its interaction with HPV infection in determining the susceptibility of cervical cancer in Chinese Han populationDisease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial 17 April 2012Volume 156, Issue 8 Page: 604-605 Keywords Cancer prevention Cancer screening Cell biology Cervical cancer Cervical cancer screening Cervical intraepithelial neoplasia Conflicts of interest Human papillomavirus Lesions Triage ePublished: 17 April 2012 Issue Published: 17 April 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...